Sandoz's biosimilar etanercept enters late-stage study

06/25/2013 | Reuters · RTT News

Novartis' generics unit Sandoz initiated a late-stage trial to confirm the biosimilarity of its version of etanercept with Amgen's Enbrel. The international trial will involve the treatment of moderate to severe chronic plaque-type psoriasis. Sandoz intends to use the results to support regulatory filings in the U.S. and Europe.

View Full Article in:

Reuters · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA